Pancholi, S., Leal, M. F., Ribas, R., Simigdala, N., Schuster, E., Chateau-Joubert, S., . . . Martin, L. (2020). Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Res.
Chicago Style aipamenaPancholi, Sunil, et al. "Correction To: Combination of MTORC1/2 Inhibitor Vistusertib Plus Fulvestrant in Vitro and in Vivo Targets Oestrogen Receptor-positive Endocrine-resistant Breast Cancer." Breast Cancer Res 2020.
MLA aipamenaPancholi, Sunil, et al. "Correction To: Combination of MTORC1/2 Inhibitor Vistusertib Plus Fulvestrant in Vitro and in Vivo Targets Oestrogen Receptor-positive Endocrine-resistant Breast Cancer." Breast Cancer Res 2020.